BDBM284013 US10023570, Example 23::US10174027, Example 23

SMILES Cn1cc(cn1)-c1cc(-c2ccc(nc2)N2CCN(CC2)C(=O)C[C@H](N)c2ccccc2)c2c(cnn2c1)C#N

InChI Key InChIKey=SAXJLFBPLXUAEK-MHZLTWQESA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 284013   

TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM284013(US10023570, Example 23 | US10174027, Example 23)
Affinity DataIC50:  3.80nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM284013(US10023570, Example 23 | US10174027, Example 23)
Affinity DataIC50:  26.6nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM284013(US10023570, Example 23 | US10174027, Example 23)
Affinity DataIC50:  26.6nMAssay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM284013(US10023570, Example 23 | US10174027, Example 23)
Affinity DataIC50:  26.6nMAssay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM284013(US10023570, Example 23 | US10174027, Example 23)
Affinity DataIC50:  3.80nMAssay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM284013(US10023570, Example 23 | US10174027, Example 23)
Affinity DataIC50:  3.80nMAssay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent